Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status

BACKGROUND: Plasma biomarkers have emerged as promising screening tools for Alzheimer’s disease (AD) because of their potential to detect amyloid β (Aβ) accumulation in the brain. One such candidate is the plasma Aβ42/40 ratio (Aβ42/40). Unlike previous research that used traditional immunoassay, re...

Descripción completa

Detalles Bibliográficos
Autores principales: Bun, Shogyoku, Ito, Daisuke, Tezuka, Toshiki, Kubota, Masahito, Ueda, Ryo, Takahata, Keisuke, Moriguchi, Sho, Kurose, Shin, Momota, Yuki, Suzuki, Natsumi, Morimoto, Ayaka, Hoshino, Yuka, Seki, Morinobu, Mimura, Yu, Shikimoto, Ryo, Yamamoto, Yasuharu, Hoshino, Takayuki, Sato, Yoshiaki, Tabuchi, Hajime, Mimura, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476307/
https://www.ncbi.nlm.nih.gov/pubmed/37667408
http://dx.doi.org/10.1186/s13195-023-01296-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476307/
https://www.ncbi.nlm.nih.gov/pubmed/37667408
http://dx.doi.org/10.1186/s13195-023-01296-5

Ejemplares similares